Clinical Outcomes: Publications

RECELL® SYSTEM KNOWLEDGE BANK

Discover content that is distributed for public review, including publications in medical journals that provide a snapshot of AVITA Medical and results from the RECELL® System.

BURNS

  1. Gittings et al. Burns. The efficacy of resistance training in addition to usual care for adults with acute burn injury: A randomised control trial. 2021 Feb; 47(1):84-100 https://www.sciencedirect.com/science/article/abs/pii/S0305417920300085
  2. Holmes et al. Burns. Demonstration of the safety and effectiveness of the RECELL® System combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. 2019 Jun;45(4):772-782. doi: 10.1016/j.burns.2018.11.002
    https://pubmed.ncbi.nlm.nih.gov/30578048/
  3. Kowal et al. Adv Ther. Cost-Effectiveness of the Use of Autologous Cell Harvesting Device Compared to Standard of Care for Treatment of Severe Burns in the United States. 2019 May 7. doi: 10.1007/s12325-019-00961-2
    https://link.springer.com/article/10.1007/s12325-019-00961-2
  4. Holmes et al. J Burn Care Res. A Comparative Study of the RECELL® Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries. 2018 Aug 17;39(5):694-702
    https://pubmed.ncbi.nlm.nih.gov/29800234/
  5. Sood et. al. Wounds. A comparative study of spray keratinocytes and autologous meshed split-thickness skin graft in the treatment of acute burn injuries. 2015 Feb:27(2):31-40
    https://pubmed.ncbi.nlm.nih.gov/25785905/
  6. Lim et. al. Burns. Is the length of time in acute burn surgery associated with poorer outcomes? 2014;40(2):235-40 https://pubmed.ncbi.nlm.nih.gov/23876784/
  7. Johnstone et al. Burns. Successful application of keratinocyte suspension using autologous fibrin spray. 2017;43(3):e27-e30
    https://pubmed.ncbi.nlm.nih.gov/27345775/

PRESENTED AT ABA 2020 AND PUBLISHED IN THE JBCR SUPPLEMENT

  1. Holmes et al. J Burn Care Res. Real World Treatment Trends for Patients TBSA ≤ 20%: Evaluating Important Shifts in Care and Budget Impact of ASCS Adoption. 2020 Mar 41; Suppl 1: S115.
    https://academic.oup.com/jbcr/article-abstract/41/Supplement_1/S115/5775841?redirectedFrom=fulltext
  2. Van Hoorebeke et al. The Faces of Autologous Skin Cell Suspension as Epidermal Grafts. J Burn Care Res. Volume 41, Issue Supplement_1, March 2020, Pages S195–S196, https://doi.org/10.1093/jbcr/iraa024.312

PRESENTED AT ABA 2019 AND PUBLISHED IN THE JBCR SUPPLEMENT

  1. Foster et al. J Burn Care Res. Budget impact of autologous cell harvesting device (ACHD) use versus standard of care (SOC) for treatment of severe burns: A case study for the Arizona Burn Center. 2019 Apr 40; Suppl 1: S165–S166.
    https://academic.oup.com/jbcr/article-abstract/40/Supplement_1/S165/5372165?redirectedFrom=fulltext

PRESENTED AT ABA 2018 AND PUBLISHED IN THE JBCR SUPPLEMENT

  1. Hickerson et al. J Burn Care Res. A Comparative Study of Autologous Skin Cell Suspension to Split-thickness Autografting in the Treatment of Acute Burns. 2018 Apr 39; Suppl 1: S1.
    https://academic.oup.com/jbcr/article-abstract/39/suppl_1/S1/4965292
  2. Holmes et al. J Burn Care Res. Demonstration of the Safety and Effectiveness of Autologous Skin Cell Suspension Combined with Meshed Skin Grafts for the Reduction of Donor Area in the Treatment of Acute Burns. 2018 Apr 39; Suppl 1: S60.
    https://academic.oup.com/jbcr/article-abstract/39/suppl_1/S60/4965404?redirectedFrom=fulltext

For additional information, please review our Abstract and Publications libraries.

PATIENT OUTCOMES

AVITA icons abstracts

ABSTRACTS

AVITA icons publications

PUBLICATIONS

AVITA icons videos

VIDEOS

AVITA icons abstracts

HEALTH ECONOMICS

IMPORTANT SAFETY INFORMATION (United States)

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds. The RECELL® device is used by an appropriately-licensed healthcare professional at the patient’s point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients.

CONTRAINDICATIONS: RECELL® is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann’s) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions.

WARNINGS AND PRECAUTIONS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL® is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL® Enzyme is animal derived and freedom from infectious agents cannot be guaranteed.

PRECAUTIONS: RECELL® is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL® without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, and in patients younger than 28 days of age (neonates).

SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL® have not been established for treatment of acute thermal partial-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions For Use. Please be aware that any indication for RECELL® outside of the United States may differ from the US indication. Please see the Instructions for Use for each country for the specific indication of RECELL®.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to AVITA, its subsidiaries or affiliates. No use of any AVITA trademark, trade name, or trade dress in this site may be made without the prior written authorization of AVITA, except to identify the product or services of the company.
©Copyright 2022 AVITA Medical. All Rights Reserved.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to AVITA, its subsidiaries or affiliates. No use of any AVITA trademark, trade name, or trade dress in this site may be made without the prior written authorization of AVITA, except to identify the product or services of the company.
©Copyright 2022 AVITA Medical. All Rights Reserved.